Anemia is an indication for drug development with over 340 pipeline drugs currently active. According to GlobalData, preregistered drugs for Anemia have a 92% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Anemia compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Anemia

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anemia overview

Anemia is a condition characterized by insufficient healthy red blood cells or hemoglobin to effectively transport oxygen to the body’s tissues. Hemoglobin, a protein in red blood cells, carries oxygen from the lungs to organs. Symptoms include tiredness, weakness, shortness of breath, and pale or yellowish skin. Various forms of anemia exist, each with its own cause and severity. Treatments may involve supplements or medical procedures. Anemia can serve as a warning sign of underlying health issues. While some forms are not preventable, maintaining a healthy diet can help prevent iron deficiency anemia and vitamin deficiency anemias. Iron-rich foods, folate, vitamin B-12, and vitamin C contribute to overall prevention.

For a complete picture of PTSR and LoA scores for drugs in Anemia, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.